Alvogen group has experienced a number of key changes in 2020. It divested its central and eastern European business to Zentiva in a major transaction (Also see "Alvogen And Zentiva Complete CEE Deal" - Generics Bulletin, 20 April, 2020.); it rebranded its business-to-business unit with a new name and identity as Adalvo (Also see "Alvogen Group Unveils Adalvo B2B Unit" - Generics Bulletin, 4 June, 2020.); and, like all firms, it has grappled with the pressures of an unpredictable coronavirus pandemic that posed a potential threat to supply-chain security.
In the first part of our exclusive interview, Alvogen chairman and CEO Robert Wessman talked about the group’s Alvotech business...
